表紙
市場調査レポート

骨粗しょう症の世界市場 (2016-2026年):骨吸収抑制薬・蛋白同化薬・その他の薬剤の収益予測

Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others

発行 Visiongain Ltd 商品コード 302716
出版日 ページ情報 英文 207 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=144.09円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
骨粗しょう症の世界市場 (2016-2026年):骨吸収抑制薬・蛋白同化薬・その他の薬剤の収益予測 Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others
出版日: 2016年04月04日 ページ情報: 英文 207 Pages
概要

当レポートでは、世界の骨粗しょう症治療薬の市場を調査し、骨粗しょう症およびその治療の概要、市場全体および薬剤クラス別の市場規模の推移と予測、市場成長への各種影響因子の分析、主要ブランドの収益規模の推移と予測、パイプラインのプロファイル、主要国別の市場背景・市場動向・市場規模推移と予測、主要企業のプロファイル、各種定性分析、専門家へのインタビューなどをまとめています。

第1章 レポート概要

第2章 骨粗しょう症:イントロダクション

  • 骨粗しょう症の有病率・発生率
  • 骨粗しょう症:サイレントキラー
  • 骨折治癒において重要な骨芽細胞
  • 骨粗しょう症の分類:種類別
  • 骨粗しょう症の分類:治療別
  • 骨粗しょう症のリスク因子

第3章 世界市場の予測

  • 市場実績
  • 市場予測
  • 市場予測:薬剤クラス別
    • 骨吸収抑制薬
    • 蛋白同化薬
    • その他
  • 市場成長推進因子・阻害因子

第4章 骨粗鬆症治療薬の収益予測

  • ビスホスホネート
    • Merck (MSD)のFosamax (Alendronate)
    • RocheのBonviva/Boniva (Ibandronate)
    • SanofiのActonel/Atelvia (Risedronate)
    • NovartisのReclast/Aclasta (Zoledronate)
    • 小野薬品工業・アステラスのRecalbon/Bonoteo (Minodronate)
  • SERM
    • Eli LillyのEvista (Raloxifene)
    • PfizerのDuavee
  • 抗RANKL抗体
    • AmgenのProlia (Denosumab)
  • 副甲状腺ホルモン (PTH)
    • Eli LillyのForteo (Teriparatide)
  • その他
    • ServierのProtelos (Strontium Ranelate)

第5章 パイプライン薬のプロファイル

  • Merck (MSD)のOdanacatib (MK 0822)
  • AmgenのRomosozumab (AMG 785)
  • Blosozumab (LY2541546)
  • Radius HealthのAbaloparatide (BA-058)
  • ZP-PTH: Parathyroid

第6章 国別市場の予測

  • 世界市場の実績・予測:地域別
  • 米国
  • EU5カ国
  • 日本
  • BRIC諸国
  • 韓国
  • その他の地域
  • 国別市場に関する考察

第7章 主要企業の予測

  • 現在の市場のリーダー
  • Eli Lilly
  • Amgen
  • UCB
  • GSK
  • Merck and Co. (MSD)
  • Allergan
  • Sanofi
  • Pfizer
  • Novartis
  • Radius Health

第8章 定性分析

  • SWOT分析
  • STEP分析

第9章 リサーチインタビュー

第10章 総論

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0105

Osteoporosis Global Market 2016-2026: Revenue Forecasts for Antiresorptives, Anabolics and Others - our new study reveals trends, R&D progress, and predicted revenues

Where is the Osteoporosis Drugs market heading? Visiongain's report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 207 page report provides 140 charts. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Osteoporosis Drugs market.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
  • Read full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
    • Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
    • Interview with Paul Mitchell, founder of Synthesis Medical, an independent healthcare consultancy
    • Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist at Pursuit Physical Therapy

image1

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets: Antiresorptive drugs, Anabolic drugs and Others. These submarkets are further broken down into bisphosphonates, selective oestrogen receptor modulators, RANKL antibodies and the parathyroid hormones.

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products' sales - what's possible for those Osteoporosis Drugs?

How will individual osteoporosis drugs perform from 2016 to 2026 at world level? Our study forecasts revenues of these 13 brands:

  • 1. Fosamax
  • 2. Boniva/Bonviva
  • 3. Actonel/Atelvia
  • 4. Reclast/Aclasta
  • 5. Recalbon/Bonoteo
  • 6. Evista
  • 7. Duavee
  • 8. Prolia
  • 9. Forteo
  • 10. Odanacatib
  • 11. Romosozumab
  • 12. Protelos
  • 13. Abaloparatide

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?

You will discover individual revenue forecasts for 12 leading national markets from 2016-2026:

  • United States (US)
  • Japan
  • Germany, France, the UK, Italy and Spain (EU5 group)
  • Brazil, Russia, India and China (BRIC countries).
  • South Korea

image2

Leading companies and the potential for market growth

You can also see which companies hold the most potential:

  • Eli Lilly
  • Amgen
  • UCB
  • GSK
  • MSD
  • Allergan
  • Sanofi
  • Pfizer
  • Novartis
  • Radius Health

Research and development - assess innovation, trends and possibilities

Our report discusses R&D, appraising technological, clinical and commercial possibilities.

Our report forecasts prominent pipeline drugs and discusses their submarkets. 3 drugs are forecasted in this chapter with other promising drugs discussed. New submarkets are also introduced; the anti-sclerostin monoclonal antibodies and the cathepsin K inhibitors.

How the Osteoporosis Drugs Market report helps you

Our new report discusses issues and events affecting the osteoporosis market. You will find quantitative and qualitative analyses on:

  • Revenue to 2026 for the global osteoporosis drugs market - discover the sales potential of that industry
  • Revenues to 2026 for the osteoporosis submarkets - find sales predictions for top treatments, seeing how they can compete and succeed
  • Revenue forecasts to 2026 for 13 individual osteoporosis drugs - find the current best selling osteoporosis drug and how this will change over the next 10 years
  • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - discover the best countries and regions for commercial expansion
  • Activities of established, rising and emerging companies - hear about firms' products, capabilities, advances and outlooks, also with industry opinions
  • Discussions of R&D - investigate progress in that industry, finding technological, clinical and commercial outlooks and opportunities
  • Analysis of what stimulates and restrains the osteoporosis market - assess challenges and strengths for those medicines, their developers, producers and sellers, helping you compete and stay ahead.
  • Patent expiries and how they will affect the market.
  • The challenges facing the market, including the entry of generics on the market.
  • How unmet medical needs will fuel growth in emerging markets over the next 10 years
  • How next generation therapies will come to dominate the market by the end of the forecast.

Table of Contents

1. Report Overview

  • 1.1 Overview of the Osteoporosis Industry and Market 2016-2026
  • 1.2 Why You should Read this Report
  • 1.3 How this Study Delivers
  • 1.4 Main Questions Answered by this Report
  • 1.5 Who is this Investigation for?
  • 1.6 Method of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated Reports
  • 1.9 About visiongain

2. Introduction to Osteoporosis

  • 2.1 Osteoporosis Prevalence and Incidence in 2015
  • 2.2 Osteoporosis: The Silent Killer
  • 2.3 Osteoblasts are Critical in Bone Healing
  • 2.4 Classifying Osteoporosis by Types
  • 2.5 Classifying Osteoporosis by Treatments
    • 2.5.1 Antiresorptive Medication
    • 2.5.2 Anabolic Medication
  • 2.6 Osteoporosis Risk Factors

3. Global Forecast for the Osteoporosis Market 2016-2026

  • 3.1 The Global Osteoporosis Drug Market in 2015
  • 3.2 The Global Osteoporosis Drug Market Forecast, 2016-2026
  • 3.3 The Global Osteoporosis Market by Main Therapeutic Class, 2016-2026
    • 3.3.1 The Antiresorptive Drug Submarket
      • 3.3.1.1 Antiresorptive Drug Submarket Forecast 2016-2026
    • 3.3.2 The Anabolic Drug Submarket
    • 3.3.2.1 Anabolic Drug Submarket Forecast 2016-2026
    • 3.3.3 The Others Submarket
    • 3.3.3.1 The Others Submarket Forecast 2016-2026
  • 3.4 Drivers and Restraints for the Global Osteoporosis Market 2016-2026

4. Individual Osteoporosis Drug Revenue Forecasts 2016-2026

  • 4.1 The Bisphosphonates Submarket
    • 4.1.1 The Bisphosphonates Revenue Forecast, 2016-2026
    • 4.1.2 Merck (MSD)'s Fosamax (Alendronate)
      • 4.1.2.1 Generic Competition for Fosamax in 2016
      • 4.1.2.2 Fosamax Market Forecast 2016-2026
    • 4.1.3 Roche's Bonviva/Boniva (Ibandronate)
      • 4.1.3.1 Boniva/Bonviva Market Forecast 2016-2026
    • 4.1.4 Sanofi's Actonel/Atelvia (Risedronate)
      • 4.1.4.1 Actonel/Atelvia Market Forecast 2016-2026
    • 4.1.5 Novartis' Reclast/Aclasta (Zoledronate)
      • 4.1.5.1 Reclast/Aclasta (Zoledronate) in the Leading National Markets, 2016
      • 4.1.5.2 Generic Competition for Reclast/Aclasta (Zoledronate), 2016
      • 4.1.5.3 Reclast/Aclasta (Zoledronate) Market Forecast 2016-2026
    • 4.1.6 Ono Pharmaceutical's/Astellas' Recalbon/Bonoteo (Minodronate)
      • 4.1.6.1 Recalbon/Bonoteo Market Forecast, 2016-2026
  • 4.2 The SERMs Submarket
    • 4.2.1 The SERMs Revenue Forecast, 2016-2026
    • 4.2.2 Eli Lilly's Evista (Raloxifene)
      • 4.2.2.1 Generic Raloxifene Slashes Evista Profits
      • 4.2.2.2 Evista Market Forecast 2016-2026
    • 4.2.3 Pfizer's Duavee
      • 4.2.3.1 Duavee Market Forecast 2016-2026
  • 4.3 The Global RANKL Antibody Market Forecast, 2016-2026
    • 4.3.1 Amgen's Prolia (Denosumab)
      • 4.3.1.1 History of Prolia (Denosumab)
      • 4.3.1.2 Prolia (Denosumab) Market Forecast 2016-2026
  • 4.4 The Parathyroid Hormone Submarket
    • 4.4.1 Parathyroid Hormone Submarket Forecast 2016-2026
    • 4.4.2 Eli Lilly's Forteo (Teriparatide)
    • 4.4.3 Forteo Market Forecast 2016-2026
    • 4.4.4 Preotact/Preos Withdrawn from the Market
  • 4.5 The Others Submarket
    • 4.5.1 The Others Submarket Forecast 2016-2026
    • 4.5.2 Servier's Protelos (Strontium Ranelate) 2016-2026
    • 4.5.3 Protelos Market Forecast 2016-2026

5. Pipeline Drugs for the Osteoporosis Market 2016-2026

  • 5.1 Merck (MSD)'s Odanacatib (MK 0822)
    • 5.1.1 Odanacatib Market Forecast 2016-2026
  • 5.2 Amgen's Romosozumab (AMG 785)
    • 5.2.1 Romosozumab Market Forecast 2016-2026
  • 5.3 Blosozumab (LY2541546)
  • 5.4 Radius Health's Abaloparatide (BA-058)
    • 5.4.1 Abaloparatide Market Forecast 2016-2026
  • 5.5 ZP-PTH: Parathyroid
    • 5.6 ZT-034: Will Need More Than Biomarkers for Approval

6. National Submarkets for the Osteoporosis Market 2016-2026

  • 6.1 The Global Osteoporosis Market by Regional Breakdown, 2015, 2020 and 2026
  • 6.2 The Global Osteoporosis Market Forecast by Regional Breakdown, 2015, 2020 and 2026
  • 6.3 The US Osteoporosis Drug Market, 2015
    • 6.3.1 The US Osteoporosis Market Forecast, 2016-2026
    • 6.3.2 The Reimbursement System of the US
    • 6.3.3 The US Must Improve Osteoporosis Preventation Measures
    • 6.3.4 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
  • 6.4 The EU5 Osteoporosis Osteoporosis Market Forecasts, 2016-2026
    • 6.4.1 The German Osteoporosis Market Forecast, 2016-2026
    • 6.4.2 The French Osteoporosis Market Forecast, 2016-2026
    • 6.4.3 The UK Osteoporosis Drug Market Forecast, 2016-2026
    • 6.4.4 The Italian Osteoporosis Market Forecast, 2016-2026
    • 6.4.5 The Spanish Osteoporosis Market Forecast, 2016-2026
  • 6.5 The Japanese Osteoporosis Drug Market, 2015
    • 6.5.1 The Japanese Osteoporosis Market Forecast, 2016-2026
    • 6.5.2 Recent Trends in the Japanese Osteoporosis Market
  • 6.6 The BRIC Countries Osteoporosis Market, 2015
    • 6.6.1 The BRIC Countries Osteoporosis Market Forecast, 2016-2026
    • 6.6.2 The Chinese Osteoporosis Market Forecast, 2016-2026
      • 6.6.2.1 Drivers of Growth in the Chinese Market
    • 6.6.3 The Indian Osteoporosis Market Forecast, 2016-2026
    • 6.6.4 The Russian Osteoporosis Market Forecast, 2016-2026
    • 6.6.5 The Brazilian Osteoporosis Market Forecast, 2016-2026
  • 6.7 The South Korean Osteoporosis Market, 2016-2026
  • 6.8 The Osteoporosis Market for the Rest of the World, 2016-2026
  • 6.9 Additional Considerations for the National Osteoporosis Markets

7. Market Leaders for the Osteoporosis Market 2016-2026

  • 7.1 Market Leaders in 2015
  • 7.2 Eli Lilly
    • 7.2.1 Eli Lilly Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.3 Amgen
    • 7.3.1 Amgen: Reacquires All Rights for Prolia from GSK
    • 7.3.2 Amgen Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.4 UCB
    • 7.4.1 UCB Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.5 GSK
  • 7.6 Merck and Co. (MSD)
    • 7.6.1 Merck (MSD) Osteoporosis Drug Sales Forecast, 2016-2026
  • 7.7 Allergan
  • 7.8 Sanofi
  • 7.9 Pfizer
  • 7.10 Novartis
  • 7.11 Radius Health

8. Qualitative Analysis of the Osteoporosis Market

  • 8.1 SWOT (Strengths, Weaknesses, Opportunities and Threats) Analysis of the Osteoporosis Market, 2016-2026
  • 8.2 STEP (Social, Technological, Economic and Political) Analysis of the Osteoporosis Market, 2016-2026

9. Research Interviews

  • 9.1 Interview with Amy Porter, CEO and Executive Director of the National Osteoporosis Foundation (NOF), US and Clare Gill, Senior Director, Marketing, Consumer and Corporate Outreach at the NOF
    • 9.1.1 On the Problem of Osteoporosis in Today's Society
    • 9.1.2 On the Work of the National Osteoporosis Foundation
    • 9.1.3 On Drug Treatments and the Prevention of Osteoporosis
  • 9.2 Interview with Paul Mitchell, Founder of Synthesis Medical Limited
    • 9.2.1 On the Work of Synthesis Medical
    • 9.2.2 On the Burden of Osteoporosis to Society
    • 9.2.3 On Education and Policy for Osteoporosis
    • 9.2.4 On Primary and Secondary Fractures
    • 9.2.5 On Drug Treatments and Innovation for Osteoporosis
  • 9.3 Interview with Cathy Yi, Orthopaedic Physical Therapy Clinical Specialist, Pursuit Physical Therapy
    • 9.3.1 On the Therapy used at Pursuit Physical Therapy
    • 9.3.2 On Primary and Secondary Fractures
    • 9.3.3 On Education and Innovation for Osteoporosis

10. Conclusions

  • 10.1 The Global Osteoporosis Market and Submarkets in 2015
  • 10.2 The Global Osteoporosis Market and Submarkets until 2026
  • 10.3 The National Markets for Osteoporosis in 2015
  • 10.4 The National Markets for Osteoporosis until 2026
  • 10.5 Leading Companies in the Osteoporosis Market
  • 10.6 Drivers for the Osteoporosis Market
  • 10.7 Challenges to Overcome for the Future Osteoporosis Drug Market
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 2.1 Mechanisms Involved in Bone Grafting
  • Table 3.1 Treatments for Osteoporosis, by Therapeutic Classes, Drug Category and Branded Drugs, 2016
  • Table 3.2 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.3 The Global Osteoporosis Drug Market: Revenue ($m) and Market Shares (%) by Therapeutic Classes, 2015, 2020 and 2026
  • Table 3.4 The Global Antiresorptive Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.5 The Global Anabolic Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 3.6 The Others Submarket Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2026
  • Table 4.1 The Bisphosphonates Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.2 Fosamax Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.3 Boniva/Bonviva Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.4 Actonel/Atelvia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.5 Reclast/Aclasta Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.6 Recalbon/Bonoteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.7 The SERMs Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.8 Evista Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.9 Duavee Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.10 Prolia Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.11 The PTH Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.12 Forteo Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.13 The Others Submarket Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 4.14 Protelos Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.1 Odanacatib Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.2 Romosozumab Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 5.3 Abaloparatide Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
  • Table 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015, 2020 and 2026
  • Table 6.3 The Global Osteoporosis Drug Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.4 The US Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.5 The EU5 Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.6 The Median Ages in EU5 Nations from 1960 to 2060, by Country
  • Table 6.7 Germany Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.8 France Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.9 UK Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.10 Italy Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.11 Spain Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.12 Japan Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.13 The BRIC Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.14 China Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.15 India Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.16 Russia Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.17 Brazil Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.18 South Korea Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 6.19 RoW Osteoporosis Market Forecast: Revenue ($m), AGR (%) and CAGR (%) by Regional Market, 2016-2026
  • Table 7.1 The Eli Lilly Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.2 The Amgen Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.3 The UCB Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.4 The Merck (MSD) Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.5 The Sanofi Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.6 The Pfizer Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.7 The Novartis Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 7.8 The Radius Health Osteoporosis Market Forecast: Revenue ($m), AGR (%), Market Share (%) and CAGR (%), 2016-2026
  • Table 8.1 Strengths and Weaknesses of the Osteoporosis Market, 2016-2026
  • Table 8.2 Opportunities and Threats to the Osteoporosis Market, 2016-2026
  • Table 8.3 Social and Technological Factors of the Osteoporosis Market, 2016-2026
  • Table 8.4 Economic and Political Factors of the Osteoporosis Market, 2016-2026

List of Figures

  • Figure 1.1 Global Osteoporosis Drug Market Segmentation
  • Figure 3.1 The Global Osteoporosis Drug Market Revenue ($m) Forecast, 2016-2026
  • Figure 3.2 The Global Osteoporosis Drug Market AGR (%) Forecast, 2016-2026
  • Figure 3.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
  • Figure 3.4 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2020
  • Figure 3.5 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
  • Figure 3.6 Drivers and Restraints for the Osteoporosis Market, 2016-2026
  • Figure 4.1 The Bisphosphonates Revenue Forecast ($m), 2016-2026
  • Figure 4.2 The Bisphosphosphonates Drug Market AGR (%) Forecast, 2016-2026
  • Figure 4.3 Fosamax Revenue Forecast ($m), 2016-2026
  • Figure 4.4 Fosamax AGR (%) Forecast, 2016-2026
  • Figure 4.5 Boniva/Bonviva Revenue Forecast ($m), 2016-2026
  • Figure 4.6 Boniva/Bonviva AGR (%) Forecast, 2016-2026
  • Figure 4.7 Actonel/Ateliva Revenue Forecast ($m), 2016-2026
  • Figure 4.8 Actonel/Ateliva AGR (%) Forecast, 2016-2026
  • Figure 4.9 Reclast/Aclasta Revenue Forecast ($m), 2016-2026
  • Figure 4.10 Reclast/Aclasta AGR (%) Forecast, 2016-2026
  • Figure 4.11 Recalbon/Bonoteo Revenue Forecast ($m), 2016-2026
  • Figure 4.12 Recalbon/Bonoteo AGR (%) Forecast, 2016-2026
  • Figure 4.13 The SERMs Revenue Forecast ($m), 2016-2026
  • Figure 4.14 The SERMs AGR (%) Forecast, 2016-2026
  • Figure 4.15 Evista Revenue Forecast ($m), 2016-2026
  • Figure 4.16 Evista AGR (%) Forecast, 2016-2026
  • Figure 4.17 Duavee Revenue Forecast ($m), 2016-2026
  • Figure 4.18 Duavee AGR (%) Forecast, 2016-2026
  • Figure 4.19 Prolia Revenue Forecast ($m), 2016-2026
  • Figure 4.20 Prolia AGR (%) Forecast, 2016-2026
  • Figure 4.21 PTH Revenue Forecast ($m), 2016-2026
  • Figure 4.22 PTH AGR (%) Forecast, 2016-2026
  • Figure 4.23 Forteo Revenue Forecast ($m), 2016-2026
  • Figure 4.24 Forteo AGR (%) Forecast, 2016-2026
  • Figure 4.25 The Others Submarket Revenue Forecast ($m), 2016-2026
  • Figure 4.26 The Others Submarket AGR (%) Forecast, 2016-2026
  • Figure 4.27 Protelos Revenue Forecast ($m), 2016-2026
  • Figure 4.28 Protelos Submarket AGR (%) Forecast, 2016-2026
  • Figure 5.1 Odanacatib Revenue Forecast ($m), 2016-2026
  • Figure 5.2 Odanacatib Submarket AGR (%) Forecast, 2017-2026
  • Figure 5.3 Romosozumab Revenue Forecast ($m), 2016-2026
  • Figure 5.4 Romosozumab Submarket AGR (%) Forecast, 2017-2026
  • Figure 5.5 Abaloparatide Revenue Forecast ($m), 2016-2026
  • Figure 5.6 Abaloparatide Submarket AGR (%) Forecast, 2016-2026
  • Figure 6.1 The Global Osteoporosis Drug Market: Revenue ($m) by Leading Regional Markets, 2015, 2020 and 2026
  • Figure 6.2 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2015
  • Figure 6.3 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2020
  • Figure 6.4 The Global Osteoporosis Drug Market: Market Share (%) by Leading Regional Markets, 2026
  • Figure 6.5 The US Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.6 The US Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.7 Drivers and Restraints for the US Osteoporosis Market, 2016-2026
  • Figure 6.8 The EU5 Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.9 The EU5 Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.10 Germany Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.11 Germany Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.12 France Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.13 France Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.14 UK Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.15 UK Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.16 Italy Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.17 Italy Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.18 Spain Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.19 Spain Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.20 Japan Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.21 Japan Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.22 The BRIC Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.23 The BRIC Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.24 China Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.25 China Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.26 India Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.27 India Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.28 Russia Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.29 Russia Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.30 Brazil Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.31 Brazil Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.32 South Korea Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.33 South Korea Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 6.34 RoW Osteoporosis Market Revenue ($m) Forecast, 2016-2026
  • Figure 6.35 RoW Osteoporosis Market AGR (%) Forecast, 2016-2026
  • Figure 10.1 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2015
  • Figure 10.2 The Global Osteoporosis Market by Individual Drug Market Share (%), 2015
  • Figure 10.3 The Global Osteoporosis Drug Market Therapeutic Class Market Share (%), 2026
  • Figure 10.4 The Global Osteoporosis Drug Market Therapeutic Class Revenue ($m), 2015, 2020 and 2026
  • Figure 10.5 The Global Osteoporosis Market by Individual Drug Market Share (%), 2026
  • Figure 10.6 The Global Osteoporosis Market by National Market Share (%), 2015
  • Figure 10.7 The Global Osteoporosis Market by National Market Share (%), 2026
  • Figure 10.8 The Global Osteoporosis Market by Revenue ($m), 2015, 2020 and 2026

Companies Listed

  • AbiogenPharma S.p.A
  • Ablynx
  • Actavis
  • Ahn-Gook Pharmaceutical
  • Ajinomoto Pharmaceuticals Co
  • Allergan
  • Almirall
  • Amgen
  • Anda, Inc
  • Apotex Inc
  • Asahi Kasei
  • Astellas
  • AstraZeneca
  • Aurobindo Pharma
  • Aventis
  • Aventis Pharma Ltd
  • Azelon Pharmaceuticals
  • Banner Pharmacaps
  • Banyu
  • Barr Pharmaceuticals
  • Bayer
  • Celltech
  • Chugai Pharmaceutical Co. Ltd
  • Ciba Specialty Chemicals
  • Ciba-Geigy
  • Covington Venture Fund
  • Daiichi Sankyo
  • Dow Jones Industrial Average
  • EffRx Pharmaceuticals
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Eli Lilly Japan K.K
  • Fermenta Biotech
  • Glaxo Wellcome plc
  • GlaxoSmithKline (GSK)
  • Hoffmann-La Roche (Roche)
  • Jiangsu Hengrui Medicine Co., Ltd
  • LaboratoriosAtral
  • Lacer S.A
  • Ligand Pharmaceuticals
  • Lighthouse Capital Partners
  • Macleods Pharmaceuticals
  • Medis
  • Merck & Co (MSD)
  • Merck Frosst
  • Merck Sharp & Dohme
  • Mylan Pharmaceuticals
  • Nordic Bioscience
  • Novartis
  • Novartis International AG
  • NPS Pharmaceuticals
  • Nycomed
  • Ono Pharma
  • Orchid Healthcare
  • OsteoGeneX
  • Pfizer, Inc
  • Procter & Gamble (P&G)
  • Prospect Venture Partners
  • Qingdao Chia Tai Haier Pharmaceutical Co., Ltd
  • QS Pharma
  • Radius Health Inc.
  • Roche
  • Sandoz
  • Sanofi Pasteur
  • Sanofi S.A
  • Sanofi-Aventis
  • Sanofi-Synthélabo
  • Searle
  • Servier
  • SmithKline Beecham plc
  • Sumitomo Pharma
  • Sun Pharmaceuticals
  • Taisho
  • Taisho Pharmaceutical Holdings
  • Takeda
  • Takeda Pharmaceutical Co., Ltd
  • Tarsa
  • Teva Pharmaceutical Industries
  • UCB
  • Unigene Laboratories
  • Warner Chilcott
  • Wyeth Pharmaceuticals
  • Zosano Pharma

American Society for Bone and Mineral Research (ASBMR)

  • British National Formulary (BNF)
  • Committee to Evaluate Drugs
  • Derwent World Patent Index
  • Duke University Medical Centre
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • European Medicines Agency (EMA)
  • EMA's Committee for Medicinal Products for Human Use (CHMP)
  • Food and Drug Administration (FDA)
  • German Federal Joint Committee
  • Harvard College
  • Health Canada
  • HelpAge International
  • Institute for Quality and Efficiency in Health Care (IQWiG)
  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
  • International Osteoporosis Foundation (IOF)
  • Japanese Ministry of Health, Labour, and Welfare
  • Korean Federation of Industries
  • Mayo Clinic
  • Ministry of Civil Affairs of China
  • National Health Service (NHS)
  • National Institute for Health and Care Excellence (NICE)
  • National Osteoporosis Foundation (NOF)
  • Pedriatic Investigation Plan (PIP)
  • Paediatric Written Request
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • Plaintiffs' Steering Committee
  • Queen Elizabeth Medical Foundation
  • Sandwell General Hospital
  • The Committee for Medicinal Products for Human Use (CHMP)
  • The Committee to Evaluate Drugs (CED)
  • Unified Health System (SUS)
  • The United Nations
  • US Preventive Services Task Force
  • Washington University
  • World Bank
  • World Health Organization (WHO)
Back to Top